Page 137 - 2021_02-Haematologica-web

EASIX predicts SOS/VOD after alloSCT
AB
Figure 4. Time to sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) depending on Center for International Blood and Marrow Transplant Research (CIBMTR) score quartiles. (A) Training and (B) validation cohort. SCT: stem cell transplantation.
Figure 5. Effects of pravastatin/ursodeoxycholic acid prophylaxis (blue) compared to the training cohort (green) and the validation cohort (red). (A) Time to sinu- soidal obstruction syndrome/veno-occlusive disease (SOS/VOD) in the three cohorts. (B) Time to SOS/VOD in patients with the highest Endothelial Activation and Stress Index (EASIX) assessed at the day of alloSCT (EASIX-d0) quartiles in the three cohorts. (C) Time to non-relapse mortality (NRM) in patients with the highest EASIX-d0 quartile in the three cohorts. (D) Overall survival (OS) in patients with the highest EASIX-d0 quartile in the three cohorts. SCT: stem cell transplantation.
haematologica | 2021; 106(2)
451
AB
CD